Loading...
•
Dec 31, 2021
Zai Lab Q4 2021 Earnings Report
Zai Lab reported strong growth and execution in all areas of the business, expanded its portfolio of assets, and achieved regulatory milestones.
Key Takeaways
Zai Lab reported strong financial results for the year ended December 31, 2021. The company expanded its portfolio of potential first-in-class and/or best-in-class assets and made meaningful advances with its global pipeline. Commercial execution is gaining strong momentum for marketed products, including ZEJULA's inclusion in the NRDL for first-line ovarian cancer maintenance treatment.
Expanded portfolio with potential first-in-class and/or best-in-class assets.
Advanced global pipeline of 11 assets, including proof of concept for ZL-1102.
Deepened gastric and lung cancer franchises with four additional drug candidates.
Achieved additional regulatory submissions and approvals, including first non-oncology approval with NUZYRA®.
Zai Lab
Zai Lab
Forward Guidance
Zai Lab has set strategic priorities for 2022, including expediting medicines to patients, investing in R&D, and leveraging its position in China to accelerate revenue growth and source innovation.
Positive Outlook
- Expedite bringing medicines to patients by accelerating data readouts and regulatory filings.
- File the NDA for efgartigimod in China in mid-2022.
- Initiate a registrational study in China for bemarituzumab in first-line advanced gastric and GEJ cancer.
- Move ZL-1102 into full global development and submit up to two INDs for compounds with global rights in 2022.
- Accelerate growing revenue base and source innovation internally and externally.